Revised psychopharmacological algorithms for the treatment of mood disorders in Japan

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 1, 2008, Pages 11-18

  Motohashi, Nobutaka ^a   Shioe, Kunihiko ^a   Nakamura, Jun ^b   Ohshima, Akihiko ^c   Yamada, Kazuo ^d   Ozawa, Hiroki ^e   Someya, Toshiyuki ^f   Uchitomi, Yosuke ^g   Higuchi, Teruhiko ^h  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d Toyo Eiwa University   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g NATIONAL CANCER CENTER   (Japan)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Bipolar disorder; Japan; Major depression; Mood disorders; Psychopharmacology algorithm

Indexed keywords

BROMOCRIPTINE; BUSPIRONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUVOXAMINE; LITHIUM; MILNACIPRAN; OLANZAPINE; PAROXETINE; PINDOLOL; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; SULTOPRIDE; THYROID HORMONE; ZOTEPINE;

ADJUVANT THERAPY; ALGORITHM; ARTICLE; BIPOLAR DEPRESSION; CONSENSUS; DEPRESSIVE PSYCHOSIS; EVIDENCE BASED PRACTICE; HEALTH SURVEY; HUMAN; JAPAN; MAJOR DEPRESSION; MANIA; MOOD DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RAPID CYCLING BIPOLAR DISORDER;

EID: 45849111768     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701330791     Document Type: Article

References (50)

1. Murray CLJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
2. Higuchi T, Fujiwara Y, Iida M, et al. Algorithm for the treatment of mood disorders in Japan. Int J Psychiatr Clin Pract 1999;3:277-85.
3. Sato M, Nakane N, Hayashida M, T, et al. Algorithms for the treatment of schizophrenia in Japan. Int J Psychiatr Clin Pract 1999;3:271-6.
4. Shioe K. Pharmacotherapy of depression. Clinical Psychiatry 2006;46:1335-45 (in Japanese).
5. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disrord 2000;58:19-36.
6. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001;16:169-78.
7. Aoba A, Tanaka Y, Kageyama S, et al. A post-marketing clinical study of paroxetine hydrochloride hydrate in patients with depression or depressive episodes: A double-blind, imipramine hydrochloride-controlled, comparative study. Jpn J Clin Psychopharmacol 2004;7:831-53 (in Japanese).
8. Asakura M, Tajima O. A randomized, double-bind study of fluvoxamine maleate inpatients with depression or depressive state: A comparison in anticholinergic effects and cardiovascular adverse reactions between fluvoxamine maleate and imipramine hydrochloride. Jpn Pharmacol Ter 2005;33:773-87.
9. Otsubo T, Akimoto Y, Yamada H, et al. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. Pharmacopsychiatry 2005;38:30-5.
10. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
11. Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev 2002;1:CD001026.
12. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-80.
13. Baker CB, Tweedie R, Duval S, Woods SW. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9.
14. Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression - Update 2002. Eur Arch Psychiatry Clin Neurosci 2003;253:132-9.
15. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996;53:842-8.
16. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
17. Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996;40:151-3.
18. Segrave R, Nathan PJ. Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol 2005;20:163-74.
19. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-8.
20. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001;62:448-52.
21. The UK ECT review group. Efficacy and safety of electroconvulsive therapy in depressive disorder: a systematic review and meta-analysis. Lancet 2003;361:799-808.
22. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000;15:29-34.
23. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990;147:1203-8.
24. Anton RF Jr, Burch EA Jr. Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord 1993;28:125-31.
25. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000;61:26-9.
26. Spiker DG, Weiss JC, Delay RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-6.
27. Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003;19:139-47.
28. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73.
29. Emilien G, Maloteaux JM, Seghers A, Charles G. Lithium compared to valproic acid and carbamazepine in the treatment of mania. A statistical meta-analysis. Eur Neuropsychopharmacol 1996;6:245-52.
30. Poolsup N, Li Wan Po A, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 2000;25:139-56.
31. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003;1:CD004052.
32. Kudo Y, Ichimaru S, Kawakita Y, et al. Comparison of therapeutic effect on mania of sultopride hydrochloride with haloperidol using double-blind technique. Clin Eval 1987;15:15-36 (in Japanese).
33. Harada T, Otsuki S, Yamashita I, et al. Double-blind comparative study on antimanic effects of zotepine and lithium carbonate. Jpn J Clin Psychiatry 1994;23:1249-62 (in Japanese).
34. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003;3:CD004040.
35. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005;21:923-34.
36. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-80.
37. Yatham LN, Grossman F, Augustynus I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-7.
38. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-65.
39. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995;31:265-72.
40. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994;151:169-76.
41. Nemeroff CB, Evans DL, Guylai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
42. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-6.
43. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-12.
44. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990;147:431-4.
45. Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988;3:123-9.
46. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorders. II. Treatment of refractory rapid cycling with high-dose levothyroxine. Arch Gen Psychiatry 1990;47:435-40.
47. Morishita S, Aoki S, Watanabe S. Clonazepam as a therapeutic adjunct to improve the management of psychiatric disorders. Psychiatry Clin Neurosci 1998;52:75-8.
48. Sanger TM, Tohen M, Vieta E, et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73:155-61.
49. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-84.
50. Standish-Barry HM, Bouras N, Bridges PK, Watson JP. A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology 1983;81:258-60.